Previous close | 5.1600 |
Open | 5.0400 |
Bid | 4.9400 x N/A |
Ask | 5.4600 x N/A |
Day's range | 4.8100 - 5.0400 |
52-week range | 1.9950 - 6.5400 |
Volume | |
Avg. volume | 180 |
Market cap | 180.07M |
Beta (5Y monthly) | 0.79 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Nature Medicine published Up-LIFT pivotal trial results Submitted FDA De Novo application for ARC-EX® System Successfully raised EUR 20M in equity capital EINDHOVEN, the Netherlands, May 23, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), a medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today provided a Q1 2024 business update. “This week’s publication of Up-L
Nature Medicine published Up-LIFT pivotal trial results Company will discuss pivotal trial results during webcast this week with company leaders and study principal investigators and participants EINDHOVEN, the Netherlands, May 21, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announces that on Thursda
ARC Therapy™ shown to be safe and effective in global pivotal trial* 90% of participants improved either strength or function of upper limbs* Improvement demonstrated in participants up to 34 years post-injury* 87% of participants also reported improvement in overall quality of life* EINDHOVEN, the Netherlands, May 20, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function,